{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,5,4]],"date-time":"2026-05-04T23:12:51Z","timestamp":1777936371226,"version":"3.51.4"},"reference-count":33,"publisher":"MDPI AG","issue":"16","license":[{"start":{"date-parts":[[2021,8,12]],"date-time":"2021-08-12T00:00:00Z","timestamp":1628726400000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["JCM"],"abstract":"<jats:p>There is little evidence on the use of sodium\u2212glucose cotransporter 2 inhibitors in hospitalised patients. This work aims to analyse the glycaemic and clinical efficacy and safety of empagliflozin continuation in patients with type 2 diabetes hospitalised for acute decompensated heart failure. This real-world observational study includes patients treated using our in-hospital antihyperglycaemic regimens (basal-bolus insulin vs. empagliflozin-basal insulin) between 2017 and 2020. A propensity matching analysis was used to match a patient on one regimen with a patient on the other regimen. Our primary endpoints were the differences in glycaemic control, as measured via mean daily blood glucose levels, and differences in the visual analogue scale dyspnoea score, NT-proBNP levels, diuretic response, and cumulative urine output. Safety endpoints were also analysed. After a propensity matching analysis, 91 patients were included in each group. There were no differences in mean blood glucose levels (152.1 \u00b1 17.8 vs. 155.2 \u00b1 19.7 mg\/dL, p = 0.289). At discharge, NT-proBNP levels were lower and cumulative urine output greater in the empagliflozin group versus the basal-bolus insulin group (1652 \u00b1 501 vs. 2101 \u00b1 522 pg\/mL, p = 0.032 and 16,100 \u00b1 1510 vs. 13,900 \u00b1 1220 mL, p = 0.037, respectively). Patients who continued empagliflozin had a lower total number of hypoglycaemic episodes (36 vs. 64, p &lt; 0.001). No differences were observed in adverse events, length of hospital stay, or in-hospital deaths. For patients with acute heart failure, an in-hospital antihyperglycaemic regimen that includes continuation of empagliflozin achieved effective glycaemic control, lower NT-proBNP, and greater urine output. It was also safer, as it reduced hypoglycaemic episodes without increasing other safety endpoints.<\/jats:p>","DOI":"10.3390\/jcm10163540","type":"journal-article","created":{"date-parts":[[2021,8,12]],"date-time":"2021-08-12T10:54:41Z","timestamp":1628765681000},"page":"3540","update-policy":"https:\/\/doi.org\/10.3390\/mdpi_crossmark_policy","source":"Crossref","is-referenced-by-count":9,"title":["Efficacy and Safety of Empagliflozin Continuation in Patients with Type 2 Diabetes Hospitalised for Acute Decompensated Heart Failure"],"prefix":"10.3390","volume":"10","author":[{"ORCID":"https:\/\/orcid.org\/0000-0001-9512-8274","authenticated-orcid":false,"given":"Luis M.","family":"P\u00e9rez-Belmonte","sequence":"first","affiliation":[{"name":"Servicio de Medicina Interna, Hospital Regional Universitario de M\u00e1laga, Instituto de Investigaci\u00f3n Biom\u00e9dica de M\u00e1laga (IBIMA), Universidad de M\u00e1laga (UMA), 29010 M\u00e1laga, Spain"},{"name":"Unidad de Neurofisiolog\u00eda Cognitiva, Centro de Investigaciones M\u00e9dico Sanitarias (CIMES), Facultad de Medicina, Universidad de M\u00e1laga (UMA), 29010 M\u00e1laga, Spain"},{"name":"Servicio de Medicina Interna, Hospital Helic\u00f3pteros Sanitarios, 29660 Marbella, Spain"},{"name":"Centro de Investigaci\u00f3n Biom\u00e9dica en Red Enfermedades Cardiovasculares (CIBERCV), Instituto de Salud Carlos III, 28029 Madrid, Spain"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Michele","family":"Ricci","sequence":"additional","affiliation":[{"name":"Servicio de Medicina Interna, Hospital Regional Universitario de M\u00e1laga, Instituto de Investigaci\u00f3n Biom\u00e9dica de M\u00e1laga (IBIMA), Universidad de M\u00e1laga (UMA), 29010 M\u00e1laga, Spain"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-3722-5492","authenticated-orcid":false,"given":"Jaime","family":"Sanz-C\u00e1novas","sequence":"additional","affiliation":[{"name":"Servicio de Medicina Interna, Hospital Regional Universitario de M\u00e1laga, Instituto de Investigaci\u00f3n Biom\u00e9dica de M\u00e1laga (IBIMA), Universidad de M\u00e1laga (UMA), 29010 M\u00e1laga, Spain"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Mercedes","family":"Mill\u00e1n-G\u00f3mez","sequence":"additional","affiliation":[{"name":"Servicio de Medicina Interna, Hospital Helic\u00f3pteros Sanitarios, 29660 Marbella, Spain"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Julio","family":"Osuna-S\u00e1nchez","sequence":"additional","affiliation":[{"name":"Unidad de Neurofisiolog\u00eda Cognitiva, Centro de Investigaciones M\u00e9dico Sanitarias (CIMES), Facultad de Medicina, Universidad de M\u00e1laga (UMA), 29010 M\u00e1laga, Spain"},{"name":"Servicio de Medicina Interna, Hospital Comarcal de La Axarqu\u00eda, 29700 V\u00e9lez-M\u00e1laga, Spain"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-6892-4934","authenticated-orcid":false,"given":"M. Isabel","family":"Ruiz-Moreno","sequence":"additional","affiliation":[{"name":"Servicio de Medicina Interna, Hospital Regional Universitario de M\u00e1laga, Instituto de Investigaci\u00f3n Biom\u00e9dica de M\u00e1laga (IBIMA), Universidad de M\u00e1laga (UMA), 29010 M\u00e1laga, Spain"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-0238-0890","authenticated-orcid":false,"given":"M. Rosa","family":"Bernal-L\u00f3pez","sequence":"additional","affiliation":[{"name":"Servicio de Medicina Interna, Hospital Regional Universitario de M\u00e1laga, Instituto de Investigaci\u00f3n Biom\u00e9dica de M\u00e1laga (IBIMA), Universidad de M\u00e1laga (UMA), 29010 M\u00e1laga, Spain"},{"name":"Centro de Investigaci\u00f3n Biom\u00e9dica en Red Fisiopatolog\u00eda de la Obesidad y Nutrici\u00f3n (CIBERobn), Instituto de Salud Carlos III, 28029 Madrid, Spain"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-9333-076X","authenticated-orcid":false,"given":"Mar\u00eda D.","family":"L\u00f3pez-Carmona","sequence":"additional","affiliation":[{"name":"Servicio de Medicina Interna, Hospital Regional Universitario de M\u00e1laga, Instituto de Investigaci\u00f3n Biom\u00e9dica de M\u00e1laga (IBIMA), Universidad de M\u00e1laga (UMA), 29010 M\u00e1laga, Spain"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-6759-0514","authenticated-orcid":false,"given":"Manuel","family":"Jim\u00e9nez-Navarro","sequence":"additional","affiliation":[{"name":"Centro de Investigaci\u00f3n Biom\u00e9dica en Red Enfermedades Cardiovasculares (CIBERCV), Instituto de Salud Carlos III, 28029 Madrid, Spain"},{"name":"Unidad de Gesti\u00f3n Cl\u00ednica \u00c1rea del Coraz\u00f3n, Hospital Universitario Virgen de la Victoria, Instituto de Investigaci\u00f3n Biom\u00e9dica de M\u00e1laga (IBIMA), Universidad de M\u00e1laga (UMA), 29010 M\u00e1laga, Spain"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Juan J.","family":"G\u00f3mez-Doblas","sequence":"additional","affiliation":[{"name":"Centro de Investigaci\u00f3n Biom\u00e9dica en Red Enfermedades Cardiovasculares (CIBERCV), Instituto de Salud Carlos III, 28029 Madrid, Spain"},{"name":"Unidad de Gesti\u00f3n Cl\u00ednica \u00c1rea del Coraz\u00f3n, Hospital Universitario Virgen de la Victoria, Instituto de Investigaci\u00f3n Biom\u00e9dica de M\u00e1laga (IBIMA), Universidad de M\u00e1laga (UMA), 29010 M\u00e1laga, Spain"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-2015-7385","authenticated-orcid":false,"given":"Jos\u00e9 P.","family":"Lara","sequence":"additional","affiliation":[{"name":"Unidad de Neurofisiolog\u00eda Cognitiva, Centro de Investigaciones M\u00e9dico Sanitarias (CIMES), Facultad de Medicina, Universidad de M\u00e1laga (UMA), 29010 M\u00e1laga, Spain"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-9909-3555","authenticated-orcid":false,"given":"Ricardo","family":"G\u00f3mez-Huelgas","sequence":"additional","affiliation":[{"name":"Servicio de Medicina Interna, Hospital Regional Universitario de M\u00e1laga, Instituto de Investigaci\u00f3n Biom\u00e9dica de M\u00e1laga (IBIMA), Universidad de M\u00e1laga (UMA), 29010 M\u00e1laga, Spain"},{"name":"Centro de Investigaci\u00f3n Biom\u00e9dica en Red Fisiopatolog\u00eda de la Obesidad y Nutrici\u00f3n (CIBERobn), Instituto de Salud Carlos III, 28029 Madrid, Spain"}],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"1968","published-online":{"date-parts":[[2021,8,12]]},"reference":[{"key":"ref_1","doi-asserted-by":"crossref","first-page":"83","DOI":"10.1016\/j.ejim.2018.04.005","article-title":"National trends in diabetes mellitus hospitalization in Spain 1997\u20132010: Analysis of over 5.4 millions of admissions","volume":"60","year":"2019","journal-title":"Eur. J. Intern. Med."},{"key":"ref_2","doi-asserted-by":"crossref","first-page":"1243","DOI":"10.1111\/dom.14042","article-title":"Management of heart failure and type 2 diabetes mellitus: Maximizing complementary drug therapy","volume":"22","author":"Butler","year":"2020","journal-title":"Diabetes Obes. Metab."},{"key":"ref_3","doi-asserted-by":"crossref","first-page":"2117","DOI":"10.1056\/NEJMoa1504720","article-title":"Empagliflozin, cardiovascular outcomes, and mortality in type 2 diabetes","volume":"373","author":"Zinman","year":"2015","journal-title":"N. Engl. J. Med."},{"key":"ref_4","doi-asserted-by":"crossref","first-page":"644","DOI":"10.1056\/NEJMoa1611925","article-title":"Canagliflozin and cardiovascular and renal events in type 2 diabetes","volume":"377","author":"Neal","year":"2017","journal-title":"N. Engl. J. Med."},{"key":"ref_5","doi-asserted-by":"crossref","first-page":"2295","DOI":"10.1056\/NEJMoa1811744","article-title":"Canagliflozin and renal outcomes in type 2 diabetes and nephropathy","volume":"380","author":"Perkovic","year":"2019","journal-title":"N. Engl. J. Med."},{"key":"ref_6","doi-asserted-by":"crossref","first-page":"347","DOI":"10.1056\/NEJMoa1812389","article-title":"Dapagliflozin and Cardiovascular Outcomes in Type 2 Diabetes","volume":"380","author":"Wiviott","year":"2019","journal-title":"N. Engl. J. Med."},{"key":"ref_7","doi-asserted-by":"crossref","first-page":"1425","DOI":"10.1056\/NEJMoa2004967","article-title":"Cardiovascular Outcomes with Ertugliflozin in Type 2 Diabetes","volume":"383","author":"Cannon","year":"2020","journal-title":"N. Engl. J. Med."},{"key":"ref_8","doi-asserted-by":"crossref","first-page":"1995","DOI":"10.1056\/NEJMoa1911303","article-title":"Dapagliflozin in patients with heart failure and reduced ejection fraction","volume":"381","author":"McMurray","year":"2019","journal-title":"N. Engl. J. Med."},{"key":"ref_9","doi-asserted-by":"crossref","first-page":"2181","DOI":"10.2337\/dc07-0295","article-title":"Randomized study of basal-bolus insulin therapy in the inpatient management of patients with type 2 diabetes (RABBIT 2 trial)","volume":"30","author":"Umpierrez","year":"2007","journal-title":"Diabetes Care"},{"key":"ref_10","doi-asserted-by":"crossref","first-page":"256","DOI":"10.2337\/dc10-1407","article-title":"Randomized study of basal-bolus insulin therapy in the inpatient management of patients with type 2 diabetes undergoing general surgery (RABBIT 2 surgery)","volume":"34","author":"Umpierrez","year":"2011","journal-title":"Diabetes Care"},{"key":"ref_11","doi-asserted-by":"crossref","first-page":"3430","DOI":"10.2337\/dc13-0277","article-title":"Safety and efficacy of sitagliptin therapy for the inpatient management of general medicine and surgery patients with type 2 diabetes: A pilot, randomized, controlled study","volume":"36","author":"Umpierrez","year":"2013","journal-title":"Diabetes Care"},{"key":"ref_12","doi-asserted-by":"crossref","first-page":"125","DOI":"10.1016\/S2213-8587(16)30402-8","article-title":"Efficacy of sitagliptin for the hospital management of general medicine and surgery patients with type 2 diabetes (Sita-Hospital): A multicentre, prospective, open-label, non-inferiority randomized trial","volume":"5","author":"Pasquel","year":"2017","journal-title":"Lancet Diabetes Endocrinol."},{"key":"ref_13","doi-asserted-by":"crossref","first-page":"e000394","DOI":"10.1136\/bmjdrc-2017-000394","article-title":"Safety and efficacy of saxagliptin for glycemic control in non-critically ill hospitalized patients","volume":"5","author":"Garg","year":"2017","journal-title":"BMJ Open Diabetes Res. Care"},{"key":"ref_14","doi-asserted-by":"crossref","first-page":"837","DOI":"10.1111\/dom.13587","article-title":"Glycaemic Efficacy and Safety of Linagliptin compared to Basal-Bolus Insulin Regimen in Patients with Type 2 Diabetes Undergoing Non-Cardiac Surgery: A Multicenter Randomised Clinical Trial","volume":"21","author":"Vellanki","year":"2019","journal-title":"Diabetes Obes. Metab."},{"key":"ref_15","doi-asserted-by":"crossref","unstructured":"Lorenzo-Gonz\u00e1lez, C., Atienza-S\u00e1nchez, E., Reyes-Umpierrez, D., Vellanki, P., Davis, G.M., Pasquel, F.J., Cardona, S., Fayfman, M., Peng, L., and Umpierrez, G.E. (2020). Safety and efficacy of DDP4-Inhibitors for management of hospitalised general medicine and surgery patients with type 2 diabetes. Endocr. Pract.","DOI":"10.4158\/EP-2019-0481"},{"key":"ref_16","doi-asserted-by":"crossref","unstructured":"P\u00e9rez-Belmonte, L.M., G\u00f3mez-Doblas, J.J., Mill\u00e1n-G\u00f3mez, M., L\u00f3pez-Carmona, M.D., Guijarro-Merino, R., Carrasco-Chinchilla, F., de Teresa-Galv\u00e1n, E., Jim\u00e9nez-Navarro, M., Bernal-L\u00f3pez, M.R., and G\u00f3mez-Huelgas, R. (2018). Use of Linagliptin for the Management of Medicine Department Inpatients with Type 2 Diabetes in Real-World Clinical Practice (Lina-Real-World Study). J. Clin. Med., 7.","DOI":"10.3390\/jcm7090271"},{"key":"ref_17","doi-asserted-by":"crossref","first-page":"252","DOI":"10.1080\/07853890.2019.1613672","article-title":"Glycaemic efficacy and safety of linagliptin for the management of non-cardiac surgery patients with type 2 diabetes in a real-world setting: Lina-Surg study","volume":"51","author":"Barbancho","year":"2019","journal-title":"Ann. Med."},{"key":"ref_18","unstructured":"P\u00e9rez-Belmonte, L.M., Osuna-S\u00e1nchez, J., Rico-Robles, J.I., Ricci, M., Lara, J.P., and G\u00f3mez-Huelgas, R. (2021). Simplified glycemic management for patients with type 2 diabetes admitted for acute decompensated heart failure using linagliptin. Med. Clin., S0025-7753(21)00128-7."},{"key":"ref_19","unstructured":"P\u00e9rez-Belmonte, L.M., Osuna-S\u00e1nchez, J., Ricci, M., Mill\u00e1n-G\u00f3mez, M., L\u00f3pez-Carmona, M.D., Barbancho, M.A., Bernal-L\u00f3pez, M.R., Jansen-Chaparro, S., Lara, J.P., and G\u00f3mez-Huelgas, R. (2021). Management of older hospitalized patients with type 2 diabetes using linagliptin: Lina-Older Study. Panminerva Med."},{"key":"ref_20","doi-asserted-by":"crossref","first-page":"713","DOI":"10.1002\/ejhf.1713","article-title":"Randomised, double-blind, placebo-controlled, multicentre pilot study on the effects of empagliflozin on clinical outcomes in patients with acute decompensated heart failure (EMPA-RESPONSE-AHF)","volume":"22","author":"Damman","year":"2020","journal-title":"Eur. J. Heart Fail."},{"key":"ref_21","doi-asserted-by":"crossref","first-page":"e007048","DOI":"10.1161\/CIRCHEARTFAILURE.120.007048","article-title":"Effect of Empagliflozin as an Add-On Therapy on Decongestion and Renal Function in Patients With Diabetes Hospitalised for Acute Decompensated Heart Failure: A Prospective Randomised Controlled Study","volume":"14","author":"Tamaki","year":"2021","journal-title":"Circ. Heart Fail."},{"key":"ref_22","doi-asserted-by":"crossref","first-page":"117","DOI":"10.1056\/NEJMoa2030183","article-title":"Sotagliflozin in Patients with Diabetes and Recent Worsening Heart Failure","volume":"384","author":"Bhatt","year":"2021","journal-title":"N. Engl. J. Med."},{"key":"ref_23","unstructured":"ClinicalTrials.gov. (2021, July 30). A Study to Test the Effect of Empagliflozin in Patients Who Are in Hospital for Acute Heart Failure, Available online: https:\/\/clinicaltrials.gov\/ct2\/show\/NCT04157751?term=NCT04157751&draw=2&rank=1."},{"key":"ref_24","unstructured":"ClinicalTrials.gov. (2021, July 30). Dapagliflozin and Effect on Cardiovascular events in Acute Heart Failure-Thrombolysis in Myocardial Infarction 68 (DAPA ACT HF-TIMI 68), Available online: https:\/\/clinicaltrials.gov\/ct2\/show\/NCT04363697?term=NCT04363697&draw=2&rank=1."},{"key":"ref_25","unstructured":"ClinicalTrials.gov (2021, July 30). Dapagliflozin Heart Failure Readmission, Available online: https:\/\/clinicaltrials.gov\/ct2\/show\/NCT04249778?term=NCT04249778&draw=2&rank=1."},{"key":"ref_26","doi-asserted-by":"crossref","first-page":"86","DOI":"10.1093\/eurjhf\/hft128","article-title":"The Chronic Kidney Disease Epidemiology Collaboration equation outperforms the Modification of Diet in Renal Disease equation for estimating glomerular filtration rate in chronic systolic heart failure","volume":"16","author":"Valente","year":"2014","journal-title":"Eur. J. Heart Fail."},{"key":"ref_27","doi-asserted-by":"crossref","unstructured":"American Diabetes Association (2021). Glycemic targets: Standards of Medical Care in Diabetes-2021. Diabetes Care, 44, S73\u2013S84.","DOI":"10.2337\/dc21-S006"},{"key":"ref_28","doi-asserted-by":"crossref","first-page":"891","DOI":"10.1002\/ejhf.592","article-title":"2016 ESC Guidelines for the diagnosis and treatment of acute and chronic heart failure: The Task Force for the diagnosis and treatment of acute and chronic heart failure of the European Society of Cardiology (ESC). Developed with the special contribution of the Heart Failure Association (HFA) of the ESC","volume":"18","author":"Ponikowski","year":"2016","journal-title":"Eur. J. Heart Fail."},{"key":"ref_29","doi-asserted-by":"crossref","first-page":"1419","DOI":"10.1056\/NEJMoa0912613","article-title":"Rolofylline, an adenosine A1-receptor antagonist, in acute heart failure","volume":"363","author":"Massie","year":"2010","journal-title":"N. Engl. J. Med."},{"key":"ref_30","doi-asserted-by":"crossref","first-page":"1956","DOI":"10.1056\/NEJMoa1601895","article-title":"Effect of ularitide on cardiovascular mortality in acute heart failure","volume":"376","author":"Packer","year":"2017","journal-title":"N. Engl. J. Med."},{"key":"ref_31","doi-asserted-by":"crossref","first-page":"716","DOI":"10.1056\/NEJMoa1801291","article-title":"Effects of serelaxin in patients with acute heart failure","volume":"381","author":"Metra","year":"2019","journal-title":"N. Engl. J. Med."},{"key":"ref_32","doi-asserted-by":"crossref","unstructured":"American Diabetes Association (2021). Diabetes care in the hospital: Standards of Medical Care in Diabetes-2021. Diabetes Care, 44, S211\u2013S220.","DOI":"10.2337\/dc21-S015"},{"key":"ref_33","doi-asserted-by":"crossref","first-page":"1028","DOI":"10.1016\/j.amjmed.2011.07.011","article-title":"Hypoglycemia-associated mortality is not drug-associated but linked to comorbidities","volume":"124","author":"Boucai","year":"2011","journal-title":"Am. J. Med."}],"container-title":["Journal of Clinical Medicine"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.mdpi.com\/2077-0383\/10\/16\/3540\/pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,10,11]],"date-time":"2025-10-11T06:44:36Z","timestamp":1760165076000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.mdpi.com\/2077-0383\/10\/16\/3540"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2021,8,12]]},"references-count":33,"journal-issue":{"issue":"16","published-online":{"date-parts":[[2021,8]]}},"alternative-id":["jcm10163540"],"URL":"https:\/\/doi.org\/10.3390\/jcm10163540","relation":{"has-preprint":[{"id-type":"doi","id":"10.21203\/rs.3.rs-408104\/v1","asserted-by":"object"}]},"ISSN":["2077-0383"],"issn-type":[{"value":"2077-0383","type":"electronic"}],"subject":[],"published":{"date-parts":[[2021,8,12]]}}}